.jpg "Synthetic Biologics Inc (NYSE MKT: SYN)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Synthetic Biologics Inc (NYSE MKT: SYN) and Vascular Biogenics (NASDAQ: VBLT).
Synthetic Biologics Inc (NYSE MKT: SYN)
In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Synthetic Biologics Inc (NYSE MKT: SYN) and a price target of $1. The company’s shares closed yesterday at $0.25, close to its 52-week low of $0.19.
White said:
“We are initiating coverage of Buy rating and a $1 price target based on the outlook of its pipeline, which contains ribaxamase, an oral biologic to protect the gut microbiome from IV beta- lactam antibiotics, that could cause clostridium difficile infection (CDI). The company is also developing SYN-010 for the potential treatment of irritable bowel syndrome with constipation (IBS-C). Ribaxamase is a Phase 3-ready asset that could move forward with financing. Management expects to initiate Phase 3 in 2H19. SYN-010 has completed two Phase 2 studies. The company is currently evaluating potential strategic relationships for the development of both drugs. CDI and IBS-C are both over $1B potential market opportunities, in our opinion. The worldwide market for ribaxamase-addressable IV beta- lactam antibiotics is approximately 7.5 billion doses, by our estimates.”
According to TipRanks.com, White is a 5-star analyst with an average return of 26.5% and a 55.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Mirati Therapeutics.
Synthetic Biologics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.
See today’s analyst top recommended stocks >>
Vascular Biogenics (NASDAQ: VBLT)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Vascular Biogenics (NASDAQ: VBLT) today and set a price target of $3. The company’s shares closed yesterday at $2.20, close to its 52-week low of $2.00.
Ramakanth commented:
“We have updated our model to reflect the 1Q18 financial results. For 2018, we project deferred revenues of $948,000 and a net loss of $0.77 per share. We note that the company reported $50M in cash and cash equivalents, which we believe is sufficient to maintain operations until 1H20.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 6.0% and a 40.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Vascular Biogenics has an analyst consensus of Hold, with a price target consensus of $3.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
